Stealth BioTherapeutics Corp (NASDAQ: MITO) stock jumped 1.93% on Friday to $0.29 against a previous-day closing price of $0.28. With 1.42 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.72 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2886 whereas the lowest price it dropped to was $0.2686. The 52-week range on MITO shows that it touched its highest point at $1.58 and its lowest point at $0.16 during that stretch. It currently has a 1-year price target of $1.52. Beta for the stock currently stands at 1.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MITO was up-trending over the past week, with a rise of 21.45%, but this was up by 16.49% over a month. Three-month performance dropped to -3.19% while six-month performance fell -58.64%. The stock lost -79.47% in the past year, while it has lost -65.61% so far this year. A look at the trailing 12-month EPS for MITO yields -0.92 with Next year EPS estimates of -0.05. For the next quarter, that number is -0.02. This implies an EPS growth rate of 25.50% for this year and 3.20% for next year.
Float and Shares Shorts:
At present, 63.64 million MITO shares are outstanding with a float of 8.55 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.36 million, which was 0.49% higher than short shares on Jun 14, 2022. In addition to Ms. Irene P. McCarthy J.D. as the firm’s Pres,CEO, Sec. & Director, Mr. Henry Hess serves as its Chief Legal Counsel.
Through their ownership of 8.84% of MITO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 1.32% of MITO, in contrast to 0.07% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in MITO with 0.77% of the stake, Ikarian Capital LLC holds 501,836 shares worth 501,836. A second-largest stockholder of MITO, Brown Brothers Harriman & Co., holds 174,999 shares, controlling over 0.27% of the firm’s shares. Boothbay Fund Management LLC is the third largest shareholder in MITO, holding 48,397 shares or 0.07% stake. With a 0.07% stake in MITO, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 48,791 shares are owned by the mutual fund manager. The Lyxor/Kingdon Global Long Short E, which owns about 0.00% of MITO stock, is the second-largest Mutual Fund holder. It holds 0 shares valued at 0.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MITO since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MITO analysts setting a high price target of $2.10 and a low target of $1.00, the average target price over the next 12 months is $1.53. Based on these targets, MITO could surge 624.14% to reach the target high and rise by 244.83% to reach the target low. Reaching the average price target will result in a growth of 427.59% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MITO will report FY 2022 earnings on 03/01/2023. Analysts have provided yearly estimates in a range of -$0.05 being high and -$0.07 being low. For MITO, this leads to a yearly average estimate of -$0.06. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Stealth BioTherapeutics Corp surprised analysts by $0.01 when it reported -$0.01 EPS against a consensus estimate of -$0.02. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.01 and the low estimate is -$0.03. The average estimate for the next quarter is thus -$0.02.